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Abstract
Introduction: Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disorder caused by mutation in the RET proto-oncogene. MEN 2A 
includes medullary carcinoma of the thyroid, pheochromocytoma, and primary hyperparathyroidism. The authors present a case study 
of three family members with bilateral pheochromocytoma in the course of MEN 2A, a catecholamine crisis being the first manifestation 
of the syndrome in one of them. 
Case 1: A 30-year-old man without a history of hypertension or any other chronic medical problems was admitted to the Emergency 
Department because of a hypertensive crisis that was followed by cardiac arrest. A later diagnosis revealed bilateral pheochromocytoma 
and RET proto-oncogene mutation in codon 634. The patient underwent bilateral adrenalectomy and total thyroidectomy; the latter 
confirmed the presence of medullary carcinoma. 
Case 2: The patient underwent right adrenalectomy with the removal of a pheochromocytoma at the age of sixteen. Ten years later, 
a suspicion of pheochromocytoma in the remaining left adrenal was raised. Mutation in the RET proto-oncogene was confirmed as well. 
The patient first underwent left adrenalectomy and then she had total thyroidectomy. Postoperative histopathological examinations 
revealed pheochromocytoma and medullary carcinoma.
Case 3: Radiological and biochemical examination confirmed pheochromocytoma. Therefore, the two adrenals were removed. As muta-
tion in codon 634 was detected, the patient underwent total thyroidectomy as well. The presence of medullary carcinoma was confirmed. 
Conclusions: Pheochromocytoma is a rare and potentially lethal disease if a catecholamine crisis develops. Its recognition requires further 
investigation towards genetic syndromes, particularly MEN 2A. (Endokrynol Pol 2015; 66 (5): 462–468)
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Streszczenie
Wstęp: Zespół mnogich nowotworów gruczołów dokrewnych typu 2 (MEN 2, multiple endocrine neoplasia type 2) jest dziedzicznym zespo-
łem spowodowanym mutacją protoonkkogenu RET. Do MEN 2 zalicza się zespoły: MEN 2A, MEN 2B oraz rodzinnego raka rdzeniastego 
tarczycy (FMTC, familial medullary thyroid carcinoma). W skład zespołu MEN 2A wchodzą: rak rdzeniasty tarczycy, guz chromochłonny 
oraz pierwotna nadczynność przytarczyc. Autorzy przedstawiają historię 3 członków rodziny z obustronnym guzem chromochłonnym 
w przebiegu MEN 2A oraz przełom katecholaminowy będący pierwszą manifestację zespołu u jednego z nich. 
Przypadek 1: 30-letni mężczyzna dotychczas zdrowy, zgłosił się do Szpitalnego Oddziału Ratunkowego z powodu przełomu nadci-
śnieniowego, po którym doszło do zatrzymania krążenia. Przeprowadzona diagnostyka ujawniła obustronny guz chromochłonny oraz 
mutację protoonkogenu RET w kodonie 634. Pacjenta poddano obustronnej adrenalektomii oraz całkowitej tyreidektomii. Pooperacyjne 
badanie histopatologiczne tarczycy potwierdziło ogniska raka rdzeniastego. 
Przypadek 2: Chora przeszła prawostronną adrenalektomię z powodu pheochromocytoma. Dziesięć lat później wysunięto podejrzenie 
pheo w pozostałym nadnerczu. Stwierdzono mutację protoonkogenu RET. Chorą poddano lewostronnej adrenalektomii, a następnie 
całkowitej tyreidektomii. Pooperacyjne badania histopatologiczne potwierdziły wstępne podejrzenia pheo i raka rdzeniastego.
Przypadek 3: Zarówno badania obrazowe, jak i badania laboratoryjne budziły podejrzenie pheochromocytoma. W związku z tym, dwa 
nadnercza usunięto. Badanie histopatologiczne potwierdziło wstępne rozpoznanie. Po stwierdzeniu mutacji w kodonie 634 pacjent 
przeszedł ponadto całkowitą tyreidektomię. Stwierdzono ogniska raka rdzeniastego w materiale pooperacyjnym.
Wnioski: Pheochromocytoma jest rzadką, a ponadto potencjalnie śmiertelną chorobą, gdy wystąpi przełom katecholaminowy. Rozpoznanie 
pheochromocytoma nakazuje dalszą diagnostykę w kierunku zespołów genetycznych, w tym MEN 2A. 
(Endokrynol Pol 2015; 66 (5):  462–468)
Słowa kluczowe: zespół mnogich nowotworów gruczołów dokrewnych typu 2; przełom nadciśnieniowy; guz chromochłonny
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Introduction
Multiple endocrine neoplasia type 2 (MEN 2) is 
a multi-glandular autosomal dominant genetic 
disorder caused by mutation in the RET proto-
oncogene. It is subdivided into MEN 2A, MEN 2B, 
and familial medullary thyroid carcinoma (FMTC). 
Typically, MEN 2A includes medullary carcinoma 
of the thyroid, pheochromocytoma, and primary 
hyperparathyroidism (PHP). In MEN 2B, similarly 
to MEN 2A, medullary carcinoma of the thyroid and 
pheochromocytoma are present. Additionally, MEN 
2B includes neurofibromatosis and other congenital 
malformations. FMTC is recognised when at least two 
family members are affected by medullary carcinoma 
of the thyroid in the absence of pheochromocytoma 
or primary hyperparathyroidism [1, 2].
Multiple endocrine neoplasia type 2A is the most 
common of the three sub-types of MEN2. Yet, it is 
a rare syndrome; in the USA it affects 1/30,000–50,000 
people [3, 4]. In Poland, 50–100 new cases of MEN 2A 
can be expected annually [5, 6]. Medullary carcinoma 
of the thyroid is the most common and usually the first 
manifestation of MEN2A. It is detected in 98% of RET 
proto-oncogene mutation carriers. Pheochromocytoma 
and primary hyperparathyroidism are less common 
presentations of MEN 2A. However, the clinical presen-
tation of this syndrome is dependent on the particular 
codon mutation and can vary [2, 7–9].
The authors present a case study of three fam-
ily members with bilateral pheochromocytoma in the 
course of MEN 2A, a catecholamine crisis being the first 
manifestation of the syndrome in one of them. 
Case 1. M.K. (son), age at the moment 
of pheochromocytoma and MEN 2A 
recognition: 30 years
A 30-year-old man without a history of hypertension or 
any other chronic medical problems was admitted to the 
Emergency Department with severe abdominal pain, 
vomiting, nausea, fever, and dyspnoea. On admission, 
he had high blood pressure and tachycardia. Within 
a few hours cardiac and respiratory failure developed, 
followed by sudden cardiac arrest in the mechanism of 
asystole. Resuscitation was conducted effectively, yet the 
patient remained unconscious, demanding intubation and 
mechanical ventilation for a few days. The clinical picture 
of catecholamine crisis (high temperature, high labile 
values of blood pressure, supraventricular arrhythmias, 
cardiomyopathy) was confirmed by imaging studies — 
computer tomography revealed bilateral huge adrenal 
tumours: 88 × 73 mm in the left adrenal and 27 × 15 mm 
in the right adrenal, with typical radiologic features of 
pheochromocytoma (heterogeneous, irregular masses 
with areas of necrosis and calcification). The MR images 
raised suspicion of pheochromocytoma as well (Fig. 1, 2). 
Hormonal tests confirmed the initial diagnosis (elevated 
24-hour urine collection of metanephrine, elevated plasma 
metanephrine and chromogranin A, as shown in Table I). 
The patient underwent laparoscopic right adrenalectomy 
and classic left adrenalectomy. Histopathological examina-
tion revealed a bilateral adrenal pheochromocytoma that 
stained positive for chromogranin and synaptophysin 
with Ki-67 index < 2%. After the mutation in the RET 
proto-oncogene was confirmed, the patient underwent 
total thyroidectomy. A postoperative histopathological 
Figure 1. Abdominal MR of patient MK. Heterogeneous nodular mass lesion in left adrenal gland (83 × 73 mm) on T1 on-phase and 
on T1 out-of-phase. Analogous lesion (26 × 57 × 34 mm) with areas of necrosis in right adrenal gland
Rycina 1. MR jamy brzusznej pacjenta MK. Heterogenna guzowata zmiana w lewym nadnerczu (83 × 73 mm) — obraz T1-zależny 
w fazie i przeciwfazie. Analogiczna zmiana (26 × 57 × 34 mm) z ogniskami martwicy w prawym nadnerczu 
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study revealed multiple foci of medullary carcinoma. The 
concomitance of primary hyperparathyroidism has been 
ruled out so far (due to a normal level of parathormone 
and calcium in the plasma).
Case 2. P.K. (daughter), age at the moment 
of pheochromocytoma recognition: 16 
years; age at the moment of MEN 2A 
recognition: 28 years
P.K. is the family member in whom pheochromocytoma 
was detected first. So far she is also the youngest person 
in the family in whom the tumour has been diagnosed — 
right adrenalectomy with pheochromocytoma resection 
was performed in the year 2001 when the patient was six-
teen. Yet, at that moment she has was not been screened 
for germline mutations. From 2003 until 2013 she did not 
stay under medical supervision. In the meantime, from 
2006 episodes of tachycardia and rises in blood pressure 
were observed. An MR performed in February 2013 
revealed a pathologic mass with radiological features 
in the remaining left adrenal gland raising suspicion of 
pheochromocytoma (Fig. 2, 3). Furthermore, the MR pre-
sented focal lesions in the liver suspected of metastases. 
Meanwhile, a 24-hour urine analysis detected elevated 
excretion of metanephrine (Table I). These findings were 
followed by left adrenalectomy, which confirmed the 
initial suspicion of pheochromocytoma in the remaining 
adrenal. In order to diagnose the focal lesions in the liver, 
iodine-123-meta-iodobenzylguanidine (MIBG) scanning 
and somatostatin scintigraphy were performed. How-
ever, these examinations did not give an answer as to the 
nature of the lesions. In September 2013 a control MR 
was performed. The examination did not show a progres-
sion of the hepatic lesions and, after performing a liver 
biopsy, focal nodular hyperplasia (FHN) was diagnosed. 
In February 2014, after the mutation in the RET proto-
oncogene was confirmed, the patient underwent total 
thyroidectomy. A postoperative histopathological study 
revealed multiple foci of medullary carcinoma. Similarly 
to M.K., PHP has not been revealed so far.
Case 3. J.K. (father) age at the moment of 
MEN 2A recognition: 59 years
Bilateral masses in the adrenals were detected in 2008 
in computed tomography. Since the tumours raised sus-
picion of malignancy (atrophic changes, low 10-minute 
delayed adrenal enhancement washout of contrast in 
computer tomography), the patient was qualified for 
adrenalectomy at that time. However, because of an 
unfavourable localisation of the tumours in relation 
to renal arteries, he was dismissed from the surgery. 
In the course of the irregular diagnostic process that 
followed (it started in 2010 and finished in 2013), an 
elevated level of metanephrine in 24-hour urine collec-
tion (Table I) was stated, and the MR and MIBG images 
were typical for pheochromocytoma (Fig. 2, 4). Adding 
to this the coexisting hypertension and positive history 
of pheochromocytoma in his children, an initial diagno-
sis of bilateral pheochromocytoma was made. In May 
2013 the patient underwent bilateral adrenalectomy. 
Histopathological examination proved bilateral pheo-
chromocytoma. In January 2014, when the presence 
of the mutation in the RET proto-oncogene in exon 11 
p.C634R in the patient was confirmed, he underwent 
total thyroidectomy. Medullary carcinoma foci were 
found in the postoperative histopathological examina-
tion. The presence of PHP was ruled out at that time.
A rigorous medical history of the family revealed two 
additional deaths: J.K.’s mother (A.K) died during labour 
and her sister (U.M) died during pregnancy, which may 
be taken as confirmation of the diagnosis (Fig. 5). Further-
more, at the time, RET proto-oncogene mutation in exon 
11 p.C634R was validated in two of the three remaining 
daughters (E.K. and E.S) of J.K. Two sons of M.K. at the age 
of 9 (J.K.) and 12 (R.K.) years are waiting for gene mapping.
Discussion
The presented family members all exhibit MEN 2A. 
They meet the clinical criteria of the syndrome as each 
of them has two out of three pathologies typical for 
Figure 2. Coronal magnetic resonance images of phaeochromocytomas in JK, MK, and PK (starting from the left)
Rycina 2. MR — projekcje czołowe guzów chromochłonnych u JK, MK, PK
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MEN 2A. Furthermore, the genetic tests performed 
in the three patients, unambiguously confirm MEN 
2A regardless of the classic clinical manifestation of 
the syndrome [2, 4]. The mutation in codon 634 is the 
most common and may concern 85% of all MEN 2A 
carriers [10]. 
Pheochromocytoma is a typical manifestation of 
MEN 2A. It is estimated that 30–50% of people affected 
by this syndrome have pheochromocytoma that is 
usually bilateral or multifocal [11, 12]. Meanwhile, 
pheochromocytoma as a first manifestation of MEN 
2A occurs in 9–27% of cases [11, 13]. Mutation in co-
don 634 particularly predisposes to this tumour [11, 
14]. At the same time, pheochromocytoma related to 
the mutation in codon 634 is very likely to develop 
in young age, even in children less than ten years 
old [15]. The described family members had bilateral 
pheochromocytoma, as is typical for this mutation. 
In P.K. the tumour was detected at a relatively young 
age — she was sixteen at that time. Furthermore, all 
of them presented classic manifestations of pheo-
chromocytoma, including persistent hypertension 
(J.K.); blood pressure fluctuations and arrhythmias 
(P.K.) and even catecholamine crisis, the latter being 
the first manifestation of pheochromocytoma in M.K. 
Interestingly, pheochromocytoma related to MEN 
2A can be asymptomatic. In a study of 46 cases of 
pheochromocytoma, Pomares et al. compared isolated 
Table I. Clinical and laboratory characteristics of the K. family
Tabela I. Dane kliniczne i laboratoryjne rodziny K
Patient MK PK JK
Symptoms Catecholamine crisis Hypertension, palpitations, 
tachycardia
Hypertension, palpitations
Metanephrine
Urine mg/d
(N < 1.0)
Before treatment 4.2 3.08 2.5
After treatment < 0.35 < 0.6 < 0.25
Calcitonin
Plasma pg/mL
(N < 18.2)
Before treatment 212 79 249
After treatment < 18.2 < 2.0 < 3.2
Chromogranin A
Plasma ug/L
(N: 19–98)
Before treatment 2326 1155 165
After treatment 34 64 23
Figure 3. Abdominal MR of patient PK. Large heterogeneous nodular mass lesion (100 mm × 75 mm × 80 mm) with areas of necrosis 
and haemorrhage in left adrenal gland on T1 on-phase and on T1 out-of-phase
Rycina 3. MR jamy brzusznej pacjentki PK. Duża heterogenna guzowata zmiana (100 × 75 × 80 mm) z ogniskami martwicy 
i wylewów w lewym nadnerczu — obraz T1-zależny w fazie i przeciwfazie 
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(23 cases) vs. familial pheochromocytoma (23 cases). 
In their study, from all the MEN 2A phaeochromo-
cytomas 52% were asymptomatic, with only 35% 
presenting elevated blood pressure values. Instead, 
the majority of patients with isolated pheochromo-
cytoma were symptomatic, having hypertension 
[15]. In the general population pheochromocytoma 
is a very rare cause of hypertension; its prevalence 
in patients with hypertension varies from 0.2 to 0.6% 
[16–20] and 4–6% of adrenal incidentalomas eventu-
ally turn out to be phaeochromocytomas [18, 21, 22]. 
Meanwhile, up to 30% of phaeochromocytomas have 
a genetic background [1, 19], mainly as part of MEN 
2A, but also in von Hippel Lindau (VHL) syndrome, 
in the succinate dehydrogenase (SDH) gene family, 
or in neurofibromatosis type 1 (NF1). Therefore, the 
recognition of pheochromocytoma requires reviewing 
the patient’s family history for cases of pheochromo-
cytoma among relatives. Furthermore, the patient 
has to be examined for the presence of other clinical 
features of the mentioned syndromes. Yet, there is 
no consensus as to laboratory tests, imaging studies, 
or molecular tests that should be performed in every 
patient with pheochromocytoma and his/her relatives 
in order to detect the genetic syndrome. For example, 
according to Bryant, all patients with phaeochromo-
cytoma should have genetic counselling in order to 
detect germline mutation, and the counselling should 
cover, in particular, patients who are young, patients 
with multifocal pheochromocytoma, and patients with 
a positive family history. At the same time, according to 
her, every patient with confirmed mutation in the RET 
proto-oncogene should undergo annual screening for 
the presence of phaeochromocytoma [11]. As stated by 
Mathens et al., annual screening for phaeochromo-
cytoma should be recommended in the case of RET 
mutations in codons 918, 634, and 630 starting from 
the age of ten. In the remaining mutations it should 
begin by the age of twenty [22]. It is worth mention-
ing that more than ten years passed from the moment 
of recognition pheochromocytoma in P.K. until the 
recognition of the tumour among her relatives and 
making a final diagnosis of MEN 2A in all of them. 
The liver lesions in P.K. initially raised the suspicion of 
metastases; however, phaeochromocytoma related to 
MEN 2A is less likely to give metastases than sporadic 
pheochromocytoma [1]. Although phaeochromocy-
toma can be asymptomatic, in certain situations it can 
lead to a catecholamine crisis, as it had in the case of 
M.K. Catecholamine crises are lethal in up to 50% of 
cases. Therefore, every case of sudden hypertensive 
crisis or cardiomyopathy, especially in young people, 
should raise the suspicion of phaeochromocytoma and 
be followed by appropriate diagnostic tests. 
Figure 4. Abdominal MR of patient JK. A well-defined heterogeneous nodular lesion in right adrenal gland (36 × 34 × 35 mm) with 
features of necrosis on T1 on-phase and on T1 out-of-phase. Analogous lesion (19 × 19 × 21 mm) in left adrenal gland
Rycina 4. MR jamy brzusznej pacjenta JK. Dobrze odgraniczona heterogenna guzowata zmiana w prawym nadnerczu (36 × 34 × 35 
mm) z ogniskami martwicy — obraz T1-zależny w fazie i przeciwfazie. Analogiczna zmiana (19 × 19 × 21 mm) w lewym nadnerczu
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Medullary carcinoma of the thyroid is the second 
classic manifestation of MEN 2A. It is the most com-
mon pathology related to the syndrome — it concerns 
almost 100% of MEN 2A patients and it is usually 
multifocal [24]. Meanwhile, 25% of all medullary car-
cinoma cases are familial [25]. Interestingly, thyroid 
carcinoma was not the first manifestation of MEN 2A 
in the described family, as is the case for the majority 
of MEN 2A patients. The diagnostic process for the 
presence of medullary carcinoma was initiated when 
the pheochromocytoma turned out to be familial and 
when RET proto-oncogene mutation was detected 
in the patients. All the patients had an elevated level 
of calcitonin in the plasma. In every case, the final 
diagnosis of medullary carcinoma was made based 
on histopathological examination of the removed 
thyroid. In all patients the cancer was multifocal. 
The mutation in codon 634 is particularly related to 
high aggressiveness of the medullary carcinoma [26]. 
The detection of this mutation in the family requires 
searching for its presence in every newborn child in 
the family. If it is found, total thyroidectomy should be 
performed before five years of age because, according 
to the available literature, metastases can be revealed 
when a child is 5–6 years old [2]. In the presented fam-
ily, no cancer invasion to the lymphatic nodes of the 
neck nor metastases to distant organs had been stated 
until that time. The postoperative level of calcitonin in 
the plasma remains undetectable in all of the family 
members (Table I). 
Primary hyperparathyroidism is the third typical 
element of MEN 2A. It concerns 20–30% of all MEN 
2A patients; however, its prevalence within one family 
can vary [8, 27]. The mutation in codon 634 particularly 
predisposes to its development. PHP in MEN 2A usu-
ally begins with hyperplasia of the parathyroids and 
can be followed by the development of one or multiple 
adenomas. In the majority of cases it is asymptomatic 
at the moment of recognition [27]. Patient age at the 
time of diagnosis is relatively young; the majority of 
them are less than 35 years old [8, 25]. RET proto-
oncogene carriers have to be screened for the presence 
of PHP even if there are no biochemical or clinical 
manifestations of hyperparathyroidism. According 
to American Thyroid Association (ATA), screening 
should begin by the age of eight years in persons car-
rying a mutation in codon 630 and 634. In the case of 
other MEN 2A mutations, screening is recommended 
from the age of 20 years [2]. The check-up includes 
annual plasma calcium evaluation. Interestingly, in 
the described family, PHP has not yet been detected 
despite the mutation in codon 634. Nevertheless, the 
patients undergo typical annual screening towards 
hyperparathyroidism.
Conclusions
Phaeochromocytoma is a rare and potentially lethal 
disease if a catecholamine crisis develops. Its recogni-
tion requires further investigation towards genetic 
syndromes, particularly MEN 2A. MEN 2A should be 
considered in particular in the case of bilateral phaeo-
chromocytoma detected in young age. The detection 
of RET proto-oncogene mutation in a patient is an 
indication for the genetic screening of their relatives. 
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